- Home
- DSGN vs SEV Comparison
DSGN vs SEV Comparison
Compare DSGN & SEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- SEV
- Stock Information
- Founded
- DSGN 2017
- SEV 2019
- Country
- DSGN United States
- SEV United States
- Employees
- DSGN N/A
- SEV N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- SEV Auto Manufacturing
- Sector
- DSGN Health Care
- SEV Industrials
- Exchange
- DSGN Nasdaq
- SEV Nasdaq
- Market Cap
- DSGN 208.9M
- SEV 189.2M
- IPO Year
- DSGN 2021
- SEV N/A
- Fundamental
- Price
- DSGN $6.24
- SEV $7.52
- Analyst Decision
- DSGN
- SEV
- Analyst Count
- DSGN 0
- SEV 0
- Target Price
- DSGN N/A
- SEV N/A
- AVG Volume (30 Days)
- DSGN 196.1K
- SEV 944.6K
- Earning Date
- DSGN 11-07-2025
- SEV 01-01-0001
- Dividend Yield
- DSGN N/A
- SEV N/A
- EPS Growth
- DSGN N/A
- SEV N/A
- EPS
- DSGN N/A
- SEV N/A
- Revenue
- DSGN N/A
- SEV N/A
- Revenue This Year
- DSGN N/A
- SEV N/A
- Revenue Next Year
- DSGN N/A
- SEV N/A
- P/E Ratio
- DSGN N/A
- SEV N/A
- Revenue Growth
- DSGN N/A
- SEV N/A
- 52 Week Low
- DSGN $2.60
- SEV $3.55
- 52 Week High
- DSGN $7.77
- SEV $22.43
- Technical
- Relative Strength Index (RSI)
- DSGN 49.22
- SEV N/A
- Support Level
- DSGN $6.25
- SEV N/A
- Resistance Level
- DSGN $6.77
- SEV N/A
- Average True Range (ATR)
- DSGN 0.48
- SEV 0.00
- MACD
- DSGN 0.02
- SEV 0.00
- Stochastic Oscillator
- DSGN 49.74
- SEV 0.00
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.